EczemaNCT07703215
NPQ Plus Supplementation for Skin Health and Antioxidant Status
A study testing NPQ Plus in people with Eczema and Atopic Dermatitis, run by N REMEDIER (M) SDN BHD at 1 site in Malaysia.
Trial summary
This study evaluated the effects of NPQ Plus supplementation on skin health, antioxidant status, fatigue, and self-perceived well-being in healthy adults with skin concerns. NPQ Plus is a multi-component nutraceutical formulation containing polyphenols (Oligonol®), nicotinamide mononucleotide (NMN; RevAge®)… Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Eczema, Atopic Dermatitis, Skin Health
- What is being tested?
- NPQ Plus
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 1 siteMalaysia
- Study dates
- 1 Jan 2026to 30 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Experiencing at least one skin concern (e.g., itchiness, dryness, roughness, flaking, or skin cracking) within the previous 3 months.
- Willing and able to consume one sachet of NPQ Plus daily for 12 weeks.
- Willing to attend all scheduled study visits and assessments.
- Able to understand the study procedures and provide written informed consent.
Who cannot join
- Consumption of dietary supplements intended to improve skin health within the previous 3 months.
- Pregnant or breastfeeding women.
- Known allergy or hypersensitivity to any ingredient in NPQ Plus.
- Presence of any medical condition or concurrent medication that, in the opinion of the investigator, could interfere with study participation or outcome assessments.
- Participation in another clinical study within the previous 3 months.
- Unable or unwilling to comply with the study protocol.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effects of NPQ Plus Supplementation on Skin Health, Antioxidant Status, Fatigue and Self-Perceived Well-being: A Single-Arm Prospective Interventional Study
This study evaluated the effects of NPQ Plus supplementation on skin health, antioxidant status, fatigue, and self-perceived well-being in healthy adults with skin concerns. NPQ Plus is a multi-component nutraceutical formulation containing polyphenols (Oligonol®), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex), which are known to possess antioxidant and cellular protective properties.
This was a single-arm, open-label, prospective interventional study involving 55 participants. Subjects consumed one sachet of NPQ Plus daily for 12 weeks. Assessments were performed at baseline and at Weeks 4, 8, and 12. Skin health was evaluated using the Patient-Oriented Eczema Measure (POEM), visual analogue scale (VAS), and objective skin biophysical measurements including skin elasticity, hydration, transepidermal water loss (TEWL), pigmentation, inflammation, and sebum secretion. Antioxidant status was assessed by measuring total antioxidant capacity (TAOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Fatigue symptoms and self-perceived improvements in skin health, sleep quality, and overall well-being were also evaluated.
Read the detailed description
Skin aging is influenced by intrinsic aging processes and environmental stressors, including ultraviolet radiation, pollution, and oxidative stress. These factors contribute to impaired skin barrier function, reduced hydration and elasticity, inflammation, pigmentation changes, and increased oxidative damage to lipids, proteins, and DNA. Nutraceutical supplementation containing antioxidant and mitochondrial-supporting bioactive compounds has emerged as a potential strategy to mitigate these changes by enhancing endogenous antioxidant defenses and supporting cellular repair mechanisms.
NPQ Plus is a multi-component nutritional supplement comprising polyphenols (Oligonol®), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). These ingredients have been reported to possess antioxidant, anti-inflammatory, and mitochondrial-supportive properties that may improve skin condition, reduce oxidative stress, and alleviate fatigue.
This completed study employed a single-arm, open-label, prospective interventional design. Fifty-five healthy adults with skin concerns were enrolled and instructed to consume one sachet of NPQ Plus daily for 12 weeks. Clinical assessments were conducted at baseline and after 4, 8, and 12 weeks of supplementation.
The primary evaluations included objective skin biophysical measurements using the Multiprobe Adapter (MPA) system, consisting of skin elasticity (Cutometer®), skin hydration (Corneometer®), transepidermal water loss (Tewameter®), skin inflammation and pigmentation (Mexameter®), and sebum secretion (Sebumeter®). Patient-reported skin outcomes were assessed using the Patient-Oriented Eczema Measure (POEM), visual analogue scale (VAS), and self-perceived improvements in skin health.
Systemic antioxidant status and oxidative damage were evaluated using saliva biomarkers, including total antioxidant capacity (TAOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale, while participants also reported changes in sleep quality and overall well-being.
The study aimed to characterize longitudinal changes following NPQ Plus supplementation across multiple domains, including skin health, antioxidant status, fatigue symptoms, and participant-reported outcomes, over the 12-week intervention period.
- Conditions
- Eczema, Atopic Dermatitis, Skin Health, Fatigue Symptom, Sleep Quality, Antioxidant Capacity
- Being tested
- NPQ Plus
- Keywords
- NPQ Plus, Nutraceutical, Skin Health, Atopic Dermatitis, Antioxidant Status, Oxidative Stress, Fatigue, Nicotinamide Mononucleotide (NMN), Pyrroloquinoline Quinone (PQQ), Coenzyme Q10, Oligonol
- Medical subject headings
- Eczema, Dermatitis, Atopic, Fatigue, Sleep Initiation and Maintenance Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NPQ PlusDietary supplement
NPQ Plus is a dietary supplement containing Oligonol® (polyphenols), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). Participants consumed one sachet orally once daily for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| NPQ Plus Supplementation | Experimental | Participants consumed one sachet of NPQ Plus orally once daily for 12 weeks. NPQ Plus is a multi-component nutraceutical formulation containing Oligonol®, nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). Assessments were performed at baseline and at Weeks 4, 8, and 12 to evaluate skin health, antioxidant status, fatigue, and self-perceived well-being. Receives: Dietary Supplement: NPQ Plus |
What is being measured
The primary outcome is the main question the study is designed to answer.
Skin Elasticity
Skin elasticity was measured using the Cutometer® (MPA580, Courage \& Khazaka, Germany). Measurements were obtained from the left cheek, right inner forearm, and dorsal neck under standardized environmental conditions. Three consecutive readings were recorded at each site and the mean value was used for analysis. Higher values indicate greater skin elasticity.
Measured: Baseline, Week 4, Week 8, and Week 12
Skin Hydration
Skin hydration was assessed using the Corneometer® CM825. Measurements were obtained from the left cheek, right inner forearm, and dorsal neck. Three readings were averaged for each anatomical site. Higher values indicate greater skin hydration.
Measured: Baseline, Week 4, Week 8, and Week 12
Transepidermal Water Loss (TEWL)
Skin barrier function was evaluated by measuring transepidermal water loss using the Tewameter® TM300. Measurements were performed under standardized environmental conditions. Lower values indicate improved skin barrier integrity.
Measured: Baseline, Week 4, Week 8, and Week 12
Skin Inflammation
Skin inflammation was assessed using the erythema index measured by the Mexameter® MX18. Lower erythema values indicate reduced skin inflammation.
Measured: Baseline, Week 4, Week 8, and Week 12
Skin Pigmentation
Skin pigmentation was evaluated using the melanin index measured by the Mexameter® MX18. Changes in melanin index were assessed throughout the intervention.
Measured: Baseline, Week 4, Week 8, and Week 12
Sebum Secretion
Sebum secretion was measured using the Sebumeter® SM815. Three measurements were obtained and averaged for each assessment site. Higher values indicate greater sebum production.
Measured: Baseline, Week 4, Week 8, and Week 12
Patient-Oriented Eczema Measure (POEM)
Skin symptoms were assessed using the Patient-Oriented Eczema Measure (POEM), a validated patient-reported questionnaire evaluating eczema severity over the previous week. Lower scores indicate less severe symptoms.
Measured: Baseline, Week 4, Week 8, and Week 12
Secondary outcomes (6)
Total Antioxidant Capacity (TAOC)
Total antioxidant capacity was determined from saliva samples using a ferric reducing antioxidant capacity (FRAC) assay. Higher values indicate greater antioxidant capacity.
Measured: Baseline, Week 4, Week 8, and Week 12
Malondialdehyde (MDA)
Lipid oxidative damage was assessed by measuring salivary malondialdehyde (MDA). Lower concentrations indicate reduced lipid peroxidation.
Measured: Baseline, Week 4, Week 8, and Week 12
3-Nitrotyrosine (3-NT)
Protein oxidative damage was assessed by measuring salivary 3-nitrotyrosine (3-NT), a biomarker of protein nitration. Lower concentrations indicate reduced protein oxidative damage.
Measured: Baseline, Week 4, Week 8, and Week 12
8-Hydroxy-2'-deoxyguanosine (8-OHdG)
Oxidative DNA damage was assessed by measuring salivary 8-hydroxy-2'-deoxyguanosine (8-OHdG). Lower concentrations indicate reduced oxidative DNA damage.
Measured: Baseline, Week 4, Week 8, and Week 12
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
Fatigue severity was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire. Lower scores indicate lower fatigue severity.
Measured: Baseline, Week 4, Week 8, and Week 12
Self-perceived Outcomes
Participants rated their overall skin health, skin itchiness and sleep quality using a visual analogue scale (VAS). Ten indicate the best possible outcome, and zero indicate the worst possible outcome.
Measured: Baseline, Week 4, Week 8, and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start1 Jan 2026
- Primary completion30 Apr 2026
- Study completion30 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for EczemaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- This was a single-arm, open-label, prospective interventional study evaluating the effects of NPQ Plus supplementation on skin health, antioxidant status, fatigue, and self-perceived well-being. Participants consumed one sachet of NPQ Plus daily for 12 weeks. Assessments were conducted at baseline and at Weeks 4, 8, and 12 to evaluate changes in skin biophysical parameters, antioxidant biomarkers, fatigue, and participant-reported outcomes.
- Masking
- None (open label)
- Enrolment
- 55 participants (actual)
Sponsor and investigators
- Lead sponsor
- N REMEDIER (M) SDN BHD
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- UCSI University, JScience Consultancy PLT
- Responsible party
- Sponsor
- Investigators
- Chung Keat Tan, PhD, Principal investigator, UCSI University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07703215
- Sponsor's protocol ID
- IEC-2025-FMHS-0019
- Status last verified
- Jul 2026
- First submitted
- 8 Jul 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual Participant Data (IPD) that underlie the published results, after de-identification, will be made available upon reasonable request to the Principal Investigator. Data sharing requests will be evaluated based on scientific merit, ethical considerations, and institutional approval.
Publications
Hu T, Wang F, Duan Q, Zhao X, Yang F. Prevalence of fatigue and perceived fatigability in older adults: a systematic review and meta-analysis. Sci Rep. 2025 Feb 9;15(1):4818. doi: 10.1038/s41598-025-88961-x.
PubMed 39924533Leo TK, Tan ESS, Amini F, Rehman N, Ng ESC, Tan CK. Effect of Rice (Oryza sativa L.) Ceramides Supplementation on Improving Skin Barrier Functions and Depigmentation: An Open-Label Prospective Study. Nutrients. 2022 Jun 30;14(13):2737. doi: 10.3390/nu14132737.
PubMed 35807914
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of NPQ Plus Supplementation on Skin Health, Antioxidant Status, Fatigue and Self-Perceived Well-being: A Single-Arm Prospective Interventional Study
- ClinicalTrials.gov ID
- NCT07703215
- Acronym / sponsor ID
- IEC-2025-FMHS-0019
- Conditions
- Eczema, Atopic Dermatitis, Skin Health, Fatigue Symptom, Sleep Quality, Antioxidant Capacity
- Keywords
- NPQ Plus, Nutraceutical, Skin Health, Atopic Dermatitis, Antioxidant Status, Oxidative Stress, Fatigue, Nicotinamide Mononucleotide (NMN)
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 55 participants (actual)
- Lead sponsor
- N REMEDIER (M) SDN BHDIndustry (pharma, biotech, devices)
- Collaborators
- UCSI University, JScience Consultancy PLT
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 30 Apr 2026 (actual)
- Study completion
- 30 Apr 2026 (actual)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluated the effects of NPQ Plus supplementation on skin health, antioxidant status, fatigue, and self-perceived well-being in healthy adults with skin concerns. NPQ Plus is a multi-component nutraceutical formulation containing polyphenols (Oligonol®), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex), which are known to possess antioxidant and cellular protective properties.
This was a single-arm, open-label, prospective interventional study involving 55 participants. Subjects consumed one sachet of NPQ Plus daily for 12 weeks. Assessments were performed at baseline and at Weeks 4, 8, and 12. Skin health was evaluated using the Patient-Oriented Eczema Measure (POEM), visual analogue scale (VAS), and objective skin biophysical measurements including skin elasticity, hydration, transepidermal water loss (TEWL), pigmentation, inflammation, and sebum secretion. Antioxidant status was assessed by measuring total antioxidant capacity (TAOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Fatigue symptoms and self-perceived improvements in skin health, sleep quality, and overall well-being were also evaluated.
Detailed description
Skin aging is influenced by intrinsic aging processes and environmental stressors, including ultraviolet radiation, pollution, and oxidative stress. These factors contribute to impaired skin barrier function, reduced hydration and elasticity, inflammation, pigmentation changes, and increased oxidative damage to lipids, proteins, and DNA. Nutraceutical supplementation containing antioxidant and mitochondrial-supporting bioactive compounds has emerged as a potential strategy to mitigate these changes by enhancing endogenous antioxidant defenses and supporting cellular repair mechanisms.
NPQ Plus is a multi-component nutritional supplement comprising polyphenols (Oligonol®), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). These ingredients have been reported to possess antioxidant, anti-inflammatory, and mitochondrial-supportive properties that may improve skin condition, reduce oxidative stress, and alleviate fatigue.
This completed study employed a single-arm, open-label, prospective interventional design. Fifty-five healthy adults with skin concerns were enrolled and instructed to consume one sachet of NPQ Plus daily for 12 weeks. Clinical assessments were conducted at baseline and after 4, 8, and 12 weeks of supplementation.
The primary evaluations included objective skin biophysical measurements using the Multiprobe Adapter (MPA) system, consisting of skin elasticity (Cutometer®), skin hydration (Corneometer®), transepidermal water loss (Tewameter®), skin inflammation and pigmentation (Mexameter®), and sebum secretion (Sebumeter®). Patient-reported skin outcomes were assessed using the Patient-Oriented Eczema Measure (POEM), visual analogue scale (VAS), and self-perceived improvements in skin health.
Systemic antioxidant status and oxidative damage were evaluated using saliva biomarkers, including total antioxidant capacity (TAOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Fatigue was assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale, while participants also reported changes in sleep quality and overall well-being.
The study aimed to characterize longitudinal changes following NPQ Plus supplementation across multiple domains, including skin health, antioxidant status, fatigue symptoms, and participant-reported outcomes, over the 12-week intervention period.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- This was a single-arm, open-label, prospective interventional study evaluating the effects of NPQ Plus supplementation on skin health, antioxidant status, fatigue, and self-perceived well-being. Participants consumed one sachet of NPQ Plus daily for 12 weeks. Assessments were conducted at baseline and at Weeks 4, 8, and 12 to evaluate changes in skin biophysical parameters, antioxidant biomarkers, fatigue, and participant-reported outcomes.
| Arm | Type | Receives |
|---|---|---|
| NPQ Plus Supplementation | Experimental | Dietary Supplement: NPQ PlusParticipants consumed one sachet of NPQ Plus orally once daily for 12 weeks. NPQ Plus is a multi-component nutraceutical formulation containing Oligonol®, nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). Assessments were performed at baseline and at Weeks 4, 8, and 12 to evaluate skin health, antioxidant status, fatigue, and self-perceived well-being. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Experiencing at least one skin concern (e.g., itchiness, dryness, roughness, flaking, or skin cracking) within the previous 3 months.
- Willing and able to consume one sachet of NPQ Plus daily for 12 weeks.
- Willing to attend all scheduled study visits and assessments.
- Able to understand the study procedures and provide written informed consent.
Key exclusion criteria (6 listed)
- Consumption of dietary supplements intended to improve skin health within the previous 3 months.
- Pregnant or breastfeeding women.
- Known allergy or hypersensitivity to any ingredient in NPQ Plus.
- Presence of any medical condition or concurrent medication that, in the opinion of the investigator, could interfere with study participation or outcome assessments.
- Participation in another clinical study within the previous 3 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NPQ PlusNPQ Plus is a dietary supplement containing Oligonol® (polyphenols), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). Participants consumed one sachet orally once daily for 12 weeks. | Dietary supplement | NPQ Plus Supplementation |
Primary outcome
Skin Elasticity
Time frame: Baseline, Week 4, Week 8, and Week 12
Skin elasticity was measured using the Cutometer® (MPA580, Courage \& Khazaka, Germany). Measurements were obtained from the left cheek, right inner forearm, and dorsal neck under standardized environmental conditions. Three consecutive readings were recorded at each site and the mean value was used for analysis. Higher values indicate greater skin elasticity.
Skin Hydration
Time frame: Baseline, Week 4, Week 8, and Week 12
Skin hydration was assessed using the Corneometer® CM825. Measurements were obtained from the left cheek, right inner forearm, and dorsal neck. Three readings were averaged for each anatomical site. Higher values indicate greater skin hydration.
Transepidermal Water Loss (TEWL)
Time frame: Baseline, Week 4, Week 8, and Week 12
Skin barrier function was evaluated by measuring transepidermal water loss using the Tewameter® TM300. Measurements were performed under standardized environmental conditions. Lower values indicate improved skin barrier integrity.
Skin Inflammation
Time frame: Baseline, Week 4, Week 8, and Week 12
Skin inflammation was assessed using the erythema index measured by the Mexameter® MX18. Lower erythema values indicate reduced skin inflammation.
Skin Pigmentation
Time frame: Baseline, Week 4, Week 8, and Week 12
Skin pigmentation was evaluated using the melanin index measured by the Mexameter® MX18. Changes in melanin index were assessed throughout the intervention.
Sebum Secretion
Time frame: Baseline, Week 4, Week 8, and Week 12
Sebum secretion was measured using the Sebumeter® SM815. Three measurements were obtained and averaged for each assessment site. Higher values indicate greater sebum production.
Patient-Oriented Eczema Measure (POEM)
Time frame: Baseline, Week 4, Week 8, and Week 12
Skin symptoms were assessed using the Patient-Oriented Eczema Measure (POEM), a validated patient-reported questionnaire evaluating eczema severity over the previous week. Lower scores indicate less severe symptoms.
6 secondary outcomes
Total Antioxidant Capacity (TAOC)
Time frame: Baseline, Week 4, Week 8, and Week 12
Malondialdehyde (MDA)
Time frame: Baseline, Week 4, Week 8, and Week 12
3-Nitrotyrosine (3-NT)
Time frame: Baseline, Week 4, Week 8, and Week 12
8-Hydroxy-2'-deoxyguanosine (8-OHdG)
Time frame: Baseline, Week 4, Week 8, and Week 12
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)
Time frame: Baseline, Week 4, Week 8, and Week 12
Self-perceived Outcomes
Time frame: Baseline, Week 4, Week 8, and Week 12
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Background: PubMed 39924533Hu T, Wang F, Duan Q, Zhao X, Yang F. Prevalence of fatigue and perceived fatigability in older adults: a systematic review and meta-analysis. Sci Rep. 2025 Feb 9;15(1):4818. doi: 10.1038/s41598-025-88961-x.
- Background: PubMed 35807914Leo TK, Tan ESS, Amini F, Rehman N, Ng ESC, Tan CK. Effect of Rice (Oryza sativa L.) Ceramides Supplementation on Improving Skin Barrier Functions and Depigmentation: An Open-Label Prospective Study. Nutrients. 2022 Jun 30;14(13):2737. doi: 10.3390/nu14132737.
- Individual participant dataSharing planned: Yes. Individual Participant Data (IPD) that underlie the published results, after de-identification, will be made available upon reasonable request to the Principal Investigator. Data sharing requests will be evaluated based on scientific merit, ethical considerations, and institutional approval.
Related trials for Eczema
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingPhase 1
A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis
Dermatitis Atopic
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chung Keat Tan, PhD principal investigator
UCSI University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NPQ Plus in people with Eczema and Atopic Dermatitis, run by N REMEDIER (M) SDN BHD at 1 site in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Skin Elasticity (time frame: Baseline, Week 4, Week 8, and Week 12). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07703215, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.